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Abstract
Diabetic nephropathy (DN) is a common complication in patients with diabetes,
and most of them need renal replacement therapy such as haemodialysis (HD).
These patients have a high tendency to develop infections and exhibit anomalies
in the immune system. The objective of this study was to assess the expression of
activation-related markers on T cells, as well as to quantify inflammatory
cytokines, before and after a single HD session in DN patients. The study
involved DN patients under HD treatment who signed an informed consent
form. Blood samples before and after one HD session were collected, to analyse
the expression of CD25, CD69 and CD71 in T cells. We also quantified IL-
12p70, IL-8, IL-10, IL-1b, TNF-a and IL-6 in serum samples using the
cytometric bead array technique. After the HD session, there was an increase in
the CD4/CD8 ratio due to significant alterations in both subsets. The relative
percentage of CD25+ cells and CD8+ CD25+ increased significantly after the
HD session, while the relative percentage of CD69 T cells decreased. There was a
significant decrease in the CD25 mean fluorescence intensity values for CD4+ T,
as well as in the case of CD71 in T cells after the HD session. Regarding cytokine
synthesis, we found a significant increase in IL-10 and IL-6 and a decrease in IL-8
after HD session. This study showed that a HD session in DN patients affects the
T cell activation status in the two major subpopulations and differentially
modulates the production of inflammatory cytokines.
Introduction
Worldwide prevalence studies indicate that there are at
least 347 million individuals with diabetes. Published data
indicate that 20–50% of patients with type 2 diabetes
develop diabetic nephropathy (DN) during their lives [1].
DN is characterized by kidney damage, which occurs as
the result of both direct and indirect actions of glucose.
These include oxidative stress, advanced glycation and
activation of some cytokines [2, 3]. DN is thus a major
cause of chronic kidney disease that progresses to end-stage
renal disease (ESRD) [4].
One of the features of renal function loss is the elevated
concentration of blood urea, which leads to the presence of
hypercytokinemia, likely due to the accumulation of
proinflammatory cytokines as a consequence of decreased
renal elimination [5–7]. Th1, Th2 and Th17 cytokines also
take part in the pathophysiology of DN [8].
Both innate and adaptative immunity are dysregulated
in patients with ESRD [9, 10]. Regarding cellular
adaptative immune response, it was shown that ESRD is
characterized by anomalies in different features, such as in
the CD4/CD8 ratio, CD4 T cell function, T cells response
to stimuli, their activation profile and impaired signals
from accessory molecules [11–13]. The pro-inflammatory
cytokines IL-1, IL-6 and TNF-a were studied in patients
under haemodialysis [14, 15]. Moreover, it was demon-
strated that among patients with ESRD, T effector memory
CD4 and CD8 T cells, as well as total CD8 T cells, were
higher in diabetic than in non-diabetic patients, strength-
ening the idea that different disease aetiologies can show
different haemodialysis effects on T cells [16].
Althoughanumberof studieswerepublishedonthe role of
T cell in type 2 DN haemodialysis [17], publications
reporting activation-related parameters on T cells and
cytokine secretion using samples from patients with ESRD
undergoing dialysis and healthy individuals generated
different results. Moreover, very few studies have focused on
the effect of a single HD treatment on T cell physiology and
cytokine production [16, 18–20]. Therefore, the main
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objective of this study was to compare the following
parameters in an homogeneous group of DN patients
regarding aetiology and treatment before and after a dialysis
session: (1) the proportions of T cells and their major
subpopulationsCD4andCD8, (2) theexpressionof activation
markers (CD25, CD69 and CD71) in total T cells and CD4
and CD8 T cell subpopulation and (3) the serum levels of the
cytokines IL-8, IL-1b, IL-6, IL-10, TNF-a and IL-12p70. To
our knowledge, this study is the first to analyse these
parameters in a homogeneous group of DN patients.
Materials and methods
Patients. The study group included 17 patients (7 men/10
women) with diabetic nephropathy (DN) undergoing hae-
modialysis at the Dialysis Center Fresenius Medical Care in
Covilh~a (a Portuguese inner city) for more than one year. All
patients were non-smokers and had diabetes mellitus type 2.
All patients had the same vascular access (intravenous
fistula), and none of them had had a transplant. Individuals
who received immunosuppressive drugs were excluded. The
mean age ( SD) was 72.4  10.2. All the patients were
informed of the objectives of the study and signed an
informed consent form. The project was submitted and
approved by the Fresenius Medical Care ethics committee in
accordance with both the Declaration of Helsinki and the
Declaration of Istanbul 2008.
T cell activation markers analysis by flow cytometry. Periph-
eral venous blood samples were collected before and after
HD, into EDTA tubes. Analysis of activation markers
analysis was carried out by four-colour flow cytometry
using phycoerythrin (PE)-conjugated anti-CD25, anti-
CD69 and anti-CD71 (Becton-Dickinson Pharmingen,
San Jose, CA, USA), peridinin chlorophyll protein
(PerCP)-conjugated anti-CD8 (Miltenyi Biotec, Bergisch
Gladbach, Germany), allophycocyanin (APC)-conjugated
anti-CD3 (Becton-Dickinson Pharmingen) and fluorescein
isothiocyanate (FITC)-conjugated anti-CD4 (Becton-Dick-
inson Pharmingen). The total blood was incubated with
each of the above antibodies on ice for 15 min in the dark,
following the manufacturer’s instructions. The cells were
then incubated in 1 ml of BD FACS (BD Biosciences, San
Jose, CA, USA) lysing solution for 15 min in the dark.
After the lysis of the red blood cells, the cell suspension
was washed twice with PBS to remove red blood cell
remnants and the leucocytes were resuspended in 400 lL of
PBS and placed on ice in the dark until acquisition.
Analysis of activation markers was carried out by four-
colour analysis using a FACSCalibur flow cytometer and
CELLQUEST software (BD Biosciences). For each sample, data
from 15000 cells were collected and analysed.
Cytokine analysis. The blood samples were collected
before and after HD session into tubes without anticoag-
ulant. Serum was separated after centrifugation at 20 °C,
3000 g for 10 min. These samples were frozen in
cryopreservation tubes until assessed by flow cytometry.
Serum IL-8, IL-1b, IL-6, IL-10, TNF-a and IL-12p70
levels were determined using the Cytometric Bead Array
Human Inflammatory Cytokines kit (Becton-Dickinson
Pharmingen, 551811), following the manufacturer’s
instructions.
Statistical analysis. To compare the relative percentage of
CD3, CD4 and CD8 cells; activation markers CD25, CD69
and CD71 in T subsets; and cytokines IL-8, IL-1b, IL-6,
IL-10, TNF-a and IL-12p70, before and after HD, we used
the Wilcoxon signed-rank test. Pearson’s and Spearman’s
rank correlation test was performed to determine the
relationships between continuous variables. P values <0.05
were considered statistically significant. SPSS version 22 was
used for data analysis.
Results
Baseline laboratory characteristics of the study population
Data regarding routine laboratory blood tests and dialysis
efficacy performed at the time of the blood collection for
the present work are presented in the Table 1. Specific
haematological parameters are presented in Table 2.
Analysis of activation markers on T cells
We analysed the effect of HD on T cells and their major
subpopulations, CD4 and CD8. There was an increase in
the percentage of CD3CD4 cells after the HD session, 62.3
(43.8–81.2) versus 68.1 (53–89) P = 0,042. Inversely, the
relative percentage of CD3CD8 decreased (33.5 (15.5–
49.7) versus 28.7 (9.2–40.8), P = 0,000056) after the HD
session. As a consequence, there was a significant increase
(26%) in the CD4/CD8 ratio, after the HD session (1.9
(0.9–5.2) versus 2.4 (1.3–9.6), 0,042. The increase in the
relative percentage of CD3-positive cells observed after the
HD was not statistically significant (Fig. 1).
Regarding the expression of activation markers on T
cells and their major subpopulations, we found statistically
significant differences in the T cell CD25 population [33.7
(4.3–58.2) versus 34.3 (11.5–64.1), P = 0,013], T CD8
CD25 cells [6.7 (1–15.4) versus 6.9 (1.1–25.4), P = 0,002]
and T CD69 cells [9 (0.4–30.2) versus 6.4 (1.1–14.7),
P = 0,022], where there was a 29% decrease in the relative
percentage after HD session (Fig. 2).
We also analysed the mean fluorescence intensity (MFI)
of the expression of activation markers in total T cells, and
CD4 and CD8 subpopulations. We found that after the
HD session, there was a significant decrease in CD4 T cells
expressing CD25 [62.5 (23.8–88.1) versus 55.3 (23–71.6),
P < 0,037]. Moreover, CD71 MFI also decreased in total
T cells [25.5 (10.9–84) versus 18.6 (6.6–49), 0,022],
as well as in CD4 T cells [25.4 (10.9–59.3) versus 18.2
(6.5–54.9), P = 0,012] and in CD8 T cells [27.8 (0–120.8)
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versus 21.4 (5.8–59.8), P = 0.03]. Concerning the other
cell populations expressing CD25, CD69 and CD71, no
significant differences were observed (Fig. 3).
Cytokine analysis
Figure 4 (A, B and C) represents serum levels of IL-10,
IL-6 and IL-8 in samples taken before and after HD which
were analysed by cytometric bead array. IL-10 (2.1 (1.4–
3.8) pg/ml versus 2.4 (1.6–4.2) pg/ml, P < 0.05) and IL-6
(6.7 (2.4–24.9) pg/ml versus 7.9 (3.3–31.4) pg/ml,
P < 0.05) concentrations increased after the HD session.
Data on IL-8 concentration showed that after the HD
session, the levels decreased significantly [18 (9.1–26.9)
pg/ml versus 10.3 (5.8–20.2) pg/ml, P < 0.05]. Significant
differences were not observed for IL-12p70, TNF-a and IL-
1b serum concentration between pre- and post-dialysis
samples (data not shown). We analysed the possible















1 8.96 6 55.39 156 7.6 155.8 40 1.67
2 8.45 4.2 133.3 216 7.4 95.8 80 1.79
3 5.17 4.6 88.44 163 7.6 129.5 80 1.80
4 7.41 3.8 175.9 167 9.1 164.4 40 1.84
5 5.71 3.4 40.11 312 8.5 263.9 No data 2.14
6 7.42 11.2 329 178 7 67.8 40 1.71
7 7.52 1 176.9 136 5.8 47.9 80 1.68
8 8.15 8.1 336.1 139 5.7 183.7 120 1.69
9 7.34 5.5 224.6 154 8.9 109.1 80 1.75
10 7.07 4.8 424.1 153 7.4 202.5 80 2.17
11 8.03 17.3 414.5 182 9 220.6 40 2.46
12 5.14 2.6 228 224 9 163.8 40 1.57
13 4.14 6.4 220.6 118 7 265.2 160 1.10
14 7.01 3.6 264.7 123 6.5 192.1 40 2.20
15 5.55 2.9 42.29 180 6.5 171.9 80 1.94
16 7.61 10.4 276 165 8 182.1 No data 1.33
17 5.56 5.8 265.6 159 8.4 255.2 80 1.83
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1 11.1 10000 71.1 0.1 4.1 21.4 3.3 3.3
2 11.2 5300 45.1 0.3 7.7 44.2 2.7 1.0
3 11.6 6700 66.5 0.4 6.1 19.8 7.2 3.4
4 13.8 6700 67.2 0.2 9.1 20.0 3.5 3.4
5 10.8 12000 61.3 0.2 5.8 30.0 2.7 2.0
6 10.9 6500 62.6 0.2 6.1 27.7 3.4 2.3
7 10.7 4900 63.4 0.1 5.4 26.1 5.0 2.4
8 12.2 6700 73.6 0.2 7.6 15.1 3.5 4.9
9 11.4 9900 59.8 0.1 7.5 30.4 2.2 2.0
10 11.1 5400 65.3 0.0 7.0 25.1 2.6 2.6
11 12.9 6000 63.5 0.2 6.9 26.0 3.4 2.4
12 12.9 6200 59.0 0.3 5.1 24.8 10.8 2.4
13 10.8 4900 61.3 0.0 2.9 34.2 1.6 1.8
14 10.5 8200 67.7 0.2 5.8 23.6 2.7 2.9
15 11.9 11400 82.7 0.1 5.8 8.9 2.5 9.3
16 12.7 10600 67.2 0.2 5.2 25.3 2.1 2.7
















NLR, neutrophil to lymphocyte ratio; WBC, white blood cells.
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correlation of cytokine levels with the haematological
parameters, and no significant correlations were obtained.
Discussion
A significant proportion of patients with diabetes ulti-
mately develop diabetic nephropathy [21]. Dialysis causes
some relevant changes in the immune system, namely in
the activation of complement [22], in the function of
monocyte-derived dendritic cells [23] and in the release of
various pro-inflammatory cytokines [24]. In this study, we
set forth to further investigate some aspects associated with
the activation of T lymphocytes, and with the levels of
serum inflammatory cytokines. Many studies have focused
on the comparison between healthy volunteers and HD
patients on these parameters, but very few have focused on
changes that occur after a single HD session in the same
individual.
Regarding the relative percentage of CD8 T cells, we
found a significant reduction after the HD session,
consistent with the previous studies [16]. However, the
results also revealed an increase in the T CD4 subset,
probably caused by the duration of the HD procedure
(about 4 h), which promoted a continuous state of
activation of T cells, affecting CD4 and CD8 subsets
differently. Also, it must be considered the probable
consequences of the blood contact with the membrane of
the dialyser and whether this contact can lead to T cell
apoptosis not equally affecting both compartments [20].
Overall, our results were consistent with other authors
regarding the CD4/CD8 ratio, showing an increase in this
value after HD session.
Due to the crucial importance of T cells in the immune
response, the study of the expression of their surface
activation markers is very important to establish immu-
nocompetence [25]; this was performed before and after the
HD session. It is important to bear in mind that antigen-
and mitogen-driven T cell activation is known to result in
the expression of activation markers in an orderly sequence:
CD69, CD25, CD71 and HLA-DR [26]. Our results
showed that HD caused an increase in the activation of
total T cells, and particularly in CD8 compartment as
measured by the CD25 expression. CD8 T cell subset could
be more susceptible to the stimulus caused by the dialyser
membrane when compared to CD4 T cells. As CD69 is the
earliest activation marker to be expressed after T cells are
stimulated and our samples were analysed at an interval of
2–6 h after blood collection, this may be a possible reason
to justify the decrease in percentage when compared to the
expression of CD25 on total T cells, which is expressed in
minutes to hours after activation. Probably time between
the collection of blood samples and flow cytometric
analysis was a limitation of the study, and future
Figure 1 Analysis of the effect of haemodialysis on the percentage of
peripheral blood CD4 and CD8 T cells by flow cytometry. Median values
of the relative percentages of total T cells, CD4 and CD8 subpopulations
and CD4/CD8 ratio before and after HD are shown (the letter ‘p’ means
that predialysis and post-dialysis data are statistically different (P < 0.05)
n = 17).
Figure 2 Analysis of the effect of
haemodialysis on the percentage of activation
markers on T cells and their major
subpopulations by flow cytometry. Median
values of the relative percentages of expression
of CD25, CD69 and CD71 in total T cells and
CD4 and CD8 subpopulations, before and after
HD, in 17 patients with diabetes are shown
(the letter ‘p’ means that predialysis and post-
dialysis data are statistically different
(P < 0.05) n = 17).
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experiments have to be carried out in order to understand
whether this constraint may or may not have an influence
on the immunophenotyping results.
The values of mean fluorescence intensity (MFI) were
also compared before and after HD for each activation-
related molecule. This parameter is proportional to the cell
density of the molecules analysed per cell. We observed a
reduction in the MFI of T CD4CD25 cells and a decrease in
both T cell subsets regarding CD71 expression levels, after
the HD session. CD71 binds the complex Fe (APO)-
transferrin by endocytosis, delivering iron, an important
co-factor of enzymes necessary for cell growth and
metabolism. Consistent with this analysis are the results
of the last examinations performed before blood collection,
where it was verified that approximately 82% of the
patients had transferrin values below the reference values
(200–360 mg/ml). Although the value of MFI after HD
did not change significantly concerning the CD25 marker,
a P value was yielded near 0.05 (P = 0.054), which may be
an indicator that there is a tendency for this value to
decrease. To confirm this hypothesis, a higher number of
volunteers would be required.
It is well known that inflammatory cytokines are
involved in the development and progression of diabetic
nephropathy [8, 27]. We analysed the synthesis of
IL-12p70, IL-8, IL-10, IL-1b, TNF-a and IL-6 in serum
samples taken before and after a single dialysis session for
each volunteer. We found a significant increase in IL-10
and IL-6 and a decrease in IL-8 after the HD session. It was
previously reported that serological concentration of IL-6
does not undergo significant alterations, but IL-8 concen-
tration decreases following haemodialysis [18]. Regarding
IL-6, our findings are not concordant with these; however,
in this previous study, only 6 patients in a total of 29 had
diabetes mellitus, and cytokine detection was determined
by chemiluminescence enzyme immunometric assays,
contrasting with flow cytometry used in the present report.
Rysz’s study with 15 patients observed an increase in the
concentrations of IL-1b, IL-6, IL-8 and TNF-a after the 4-
h HD [19]. Adsorption evaluations of IL-1beta, IL-6 and
TNF-alpha by different membrane dialysers showed that
the HD effects are not the same [28]. Also, continuous
haemofiltration increases IL-6 plasma clearance, but not
TNF-alpha clearance [29]. These data were obtained with
diverse experimental approaches, making it impossible to
clearly understand what is really happening during HD.
An increase in IL-10 levels appears to function as a
regulating mechanism to control uraemia and the activa-
tion induced by dialysis [30]. Through the inhibition of
IL-1b, TNF-a and IL-8, involved in the activation of
granulocytes, monocytes–macrophages and NK, T and B
cells, IL-10 regulates inflammatory process [31]. Our
results are consistent with those findings, where no
significant differences occurred in the concentration of
IL-1b and TNF-a after HD, and there was a decrease in the
concentration of IL-8. Probably the fact that IL-8 has a low
molecular weight makes its diffusion through the dialysis
membrane easy to occur.
Other than our study, we found no other study
reporting IL-12p70 levels pre- and post-dialysis in the
literature. We should also consider that the fact that
dialysis did not significantly affect the concentrations of IL-
1b, TNF-a and IL-12p70 differences in our study may be
due to methodological limitations. However, the range of
detectable values by the CBA is rather wide, 20–5000 pg/
ml, making it important to determine whether values
below 20 pg/ml may or may not be physiologically
relevant. A limitation of this study is the sample size.
Thus, to confirm the consistency of these results, it is
necessary to include a larger number of patients. Never-
theless, it is worth mentioning that IL-1b and TNF-a also
remained unchanged in the Tarakcioflu report [18].
Finally, we also studied the possible correlation of
cytokine levels with haematological parameters presented
in Table 2. Regarding the neutrophil to lymphocyte ratio
(NLR) that has been gaining interest as a marker of
Figure 3 Analysis of the effect of
haemodialysis on the level of expression of
activation markers in total T cells, CD4 and
CD8 subpopulations by flow cytometry.
Values of the mean fluorescence intensity
(MFI) of T cells and their subpopulations
(CD4 and CD8) that express CD25, CD69 and
CD71, before and after HD, in 17 patients
with diabetes are shown (the letter ‘p’ means
that pre- dialysis and post-dialysis data are
statistically different (P < 0.05) n = 17).
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subclinical inflammation in chronic kidney disease such as
dialysis patients [32], we did not find any correlation
between NLR and inflammatory cytokines.
To our knowledge, our work is the first with a
homogeneous group of DN patients to analyse the expres-
sion of activation markers on T cells and their major
subpopulations, as well as the serum levels of inflammatory
cytokines, in samples taken before and after dialysis in the
same individuals. Through this study, it was found that HD
does influence the expression of the marker CD25 in T cells
and CD8 and CD69 expression on T cells. It was also found
that after one HD session, density of CD71 molecules per
cell decreased in T cells and CD25 molecules in CD4 T
cells. Moreover, it was also verified that the HD session
resulted in the increase in the concentration of IL-10 and IL-
6 and in a reduction in the concentration of IL-8 after one
HD session, possibly suggesting that these amendments are
due to contact with the dialyser membrane. Nevertheless,
the fact that there is an increase in the concentration of IL-
10 during the HD session implies that this treatment has
immunomodulatory effect in the patients.
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